Skip to main content
. 2012 Nov 26;8(2):233–240. doi: 10.2215/CJN.06640712

Figure 1.

Figure 1.

Flow chart of Ongoing Telmisartan Alone and in combination with Ramipril Global End Point Trial (ONTARGET) and the Telmisartan Randomized Assessment Study in Angiotensin-Converting Enzyme Intolerant Subjects with Cardiovascular Disease (TRANSCEND) participants showing albuminuria (ALB) status and the number of hip and pelvis fractures. ALB is defined as an albumin-to-creatinine ratio≥30 mg/g.